Shots:
- Formycon and Bioeq have submitted MAA for FYB201 (biosimilar referencing Lucentis) to EMA
- Teva will responsible for the commercialization of FYB201 in the EU which has acquired the distribution rights under its collaboration with Bioeq. Currently, Formycon has four biosimilars in development
- Formycon focuses to treat ophthalmology, immunology, and other key chronic diseases covering the entire value chain from technical development to the clinical P-III & preparing the data for marketing approval
Click here to read full press release/ article | Ref: Formycon | Image: Formycon
The post Formycon and Bioeq Report MAA Submission to EMA for FYB201 (biosimilar, ranibizumab) first appeared on PharmaShots.
